Sellas Life Sciences Group
WKN: A2PU3T / ISIN: US81642T2096SELLAS Life Sciences Group (WKN: A2PU3T)
| eröffnet am: | 07.05.22 12:59 von: | Chalifmann3 |
| neuester Beitrag: | 15.11.22 14:38 von: | Tiger |
| Anzahl Beiträge: | 11 | |
| Leser gesamt: | 5718 | |
| davon Heute: | 6 | |
bewertet mit 0 Sternen |
||
|
|
||
07.05.22 12:59
#1
Chalifmann3
SELLAS Life Sciences Group (WKN: A2PU3T)
hier in deutscland unbekannt,aber sehr interessant,was das werden koennte:
SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer
June 30, 2021 08:55 ET | Source: SELLAS Life Sciences Group, Inc.
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up
Immune Data Shows GPS Induced WT1-Specific Immune Responses with a Substantial Increase in Antigen-Reactive T-Lymphocytes Averaging +242% for CD8+ and +80.5% for CD4+ T-Cells from Baseline to 18 Weeks Post Treatment
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced promising updated clinical data and initial immunobiological data from its Phase 1/2 clinical trial with its lead asset, galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with the checkpoint inhibitor pembrolizumab (Keytruda®).
Conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J. USA (known as MSD outside of the United States and Canada), the study is investigating the combination of GPS and pembrolizumab in treating patients diagnosed with second- or third-line WT1(+) relapsed or refractory platinum-resistant, advanced metastatic ovarian cancer. The WT1 antigen is one of the most widely expressed cancer antigens in multiple malignancies and has been ranked by the National Cancer Institute as the top priority among cancer antigens for immunotherapy.
The study details are as follows:
Eleven patients (median age: 63 years) who received at least three GPS doses, the last of which was combined with pembrolizumab, were evaluated for clinical responses and three of those patients were also evaluated for immune responses.
66.7 percent of evaluable patients were refractory to or had failed their second-line therapies, and 33.3 percent failed third-line therapy or later.
All enrolled patients (100 percent) were resistant to the standard of care platinum-based therapy. Expected overall survival for patients receiving standard of care platinum-based therapy is nine to 12 months.
Median overall survival among the patients in this trial is not yet known as all patients are still alive at the time of the analysis, which period of time exceeds nine months.
Disease Control Rate
An ad hoc analysis of clinical outcomes in the cohort of 11 patients shows a disease control rate (DCR), the sum of overall response rate and rate of stable disease, of 63.6 percent, with a median follow-up of 15.4 weeks. In December 2020, the Company reported initial data showing a DCR of 87.5 percent in eight patients, with a median follow-up of 9.4 weeks. In this very difficult treatment-resistant patient population, at the time of the follow-up analysis, median progression-free survival (PFS) was 11.8 weeks. The landmark PFS rate by log-rank analysis at six months (26 weeks) was 33 percent.
Analysis of the updated data, using a validated immunohistochemistry assay during the eligibility screening period, shows that the rate of WT1 ovarian tumor positivity in this patient population remained high at approximately 63.6 percent. As of the time of this analysis, all patients are alive, and five patients (45.5 percent) are continuing to receive investigational therapy. Enrollment for this study is ongoing, with a target of approximately 20 total evaluable patients.
The safety profile of the GPS-pembrolizumab combination was similar to that seen with pembrolizumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site, consistent with previously performed clinical studies with GPS.
Immunobiological Data
CD8+ and CD4+ T-lymphocytes were isolated from peripheral blood mononuclear cells from three patients from whom samples had been collected both at baseline and at the time of the sixth GPS dose (i.e., 18 weeks after starting investigational therapy). The T-cells were assayed ex-vivo for immune responses against the pool of the four peptides that comprise GPS using the validated assay intracellular cytokine staining with fluorescence-activated single cell sorting (ICS-FACS) (Scorpion Biological Services, San Antonio, Texas), with appropriate positive and negative controls.
A total of five cytokine “channels” were used for the analysis (i.e., interferon-g, TNF-a, interleukin-2, CD107a and MIP-1b). The peptide re-challenge incubation period was seven days. At the 18-week time point versus pre-vaccination baseline, the assay demonstrated a relative increase in WT1-specific T-lymphocyte frequencies in peripheral blood averaging +242 percent (range: +104 to +385 percent across five cytokines) for CD8+ and +80.5 percent (range: +1 to +174 percent) for CD4+. There was also evidence of polyfunctional T-cell activation (increases in secretion of >2 cytokines) in two out of three patients (66 percent).
“Considering the overall poor prognosis in this particular clinical setting and based on the observed median PFS, overall survival and DCR in this study, combining GPS with the PD1 inhibitor pembrolizumab appears to be clinically promising as compared to bevacizumab-free salvage chemotherapy regimens and without the toxicity burden associated with the latter,” said Angelos Stergiou, M.D., Sc.D. h.c., President and CEO, SELLAS. “Patients treated with GPS plus pembrolizumab also appear to maintain a considerable degree of stable disease, as evidenced by the median DCR of 63.6 percent – all evaluable patients are alive. Continuing to review the clinical data will help us determine the fundamental value of the combination approach to fighting this disease. The initial trends are promising, and further maturity of the data and studying additional patients will allow us to draw more definitive conclusions regarding the clinical benefit. We expect to perform another set of similar ad hoc clinical and immunobiological analyses over the next six months as the study progresses.”
“Based on this early data, it is encouraging to see the induction of WT1-specific T-cell immune responses with the administration of GPS in combination with pembrolizumab with a validated complex ex-vivo immune response assay on peripheral blood from patients with platinum-refractory metastatic ovarian cancer who had undergone numerous prior therapies,” added Jeffrey S. Weber, M.D., Ph.D.; Deputy Director of the Perlmutter Cancer Center at New York University (NYU)-Langone Health; Co-Director of its Melanoma Research Program Center; and Chair of SELLAS’ Scientific Advisory Board. “Expansion of these results with data from additional patients, as well as at time points longer than 18 weeks (when such patient samples become available for testing), will be key in getting a more comprehensive picture of the combination immunotherapy’s biological effect.”
About Ovarian Cancer
Ovarian cancer is one of the most common gynecologic malignancies and the fifth most frequent cause of cancer death in women in the United States. Over 22,000 cases are diagnosed annually, and there are an estimated 15,500 deaths per year. The majority of patients have widespread disease at presentation. The five-year survival for the advanced-stage disease remains less than 30 percent. Combining GPS with the checkpoint inhibitor pembrolizumab, which beneficially and profoundly alters the tumor microenvironment (TME), is hypothesized to increase the proportion of patients who develop an immune response against their cancer and potentially improve their clinical outcome over pembrolizumab monotherapy, without the burden of additional toxicities in macroscopically measurable malignancies.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Keytruda® is a registered trademark of Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.
SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer
June 30, 2021 08:55 ET | Source: SELLAS Life Sciences Group, Inc.
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up
Immune Data Shows GPS Induced WT1-Specific Immune Responses with a Substantial Increase in Antigen-Reactive T-Lymphocytes Averaging +242% for CD8+ and +80.5% for CD4+ T-Cells from Baseline to 18 Weeks Post Treatment
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced promising updated clinical data and initial immunobiological data from its Phase 1/2 clinical trial with its lead asset, galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with the checkpoint inhibitor pembrolizumab (Keytruda®).
Conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J. USA (known as MSD outside of the United States and Canada), the study is investigating the combination of GPS and pembrolizumab in treating patients diagnosed with second- or third-line WT1(+) relapsed or refractory platinum-resistant, advanced metastatic ovarian cancer. The WT1 antigen is one of the most widely expressed cancer antigens in multiple malignancies and has been ranked by the National Cancer Institute as the top priority among cancer antigens for immunotherapy.
The study details are as follows:
Eleven patients (median age: 63 years) who received at least three GPS doses, the last of which was combined with pembrolizumab, were evaluated for clinical responses and three of those patients were also evaluated for immune responses.
66.7 percent of evaluable patients were refractory to or had failed their second-line therapies, and 33.3 percent failed third-line therapy or later.
All enrolled patients (100 percent) were resistant to the standard of care platinum-based therapy. Expected overall survival for patients receiving standard of care platinum-based therapy is nine to 12 months.
Median overall survival among the patients in this trial is not yet known as all patients are still alive at the time of the analysis, which period of time exceeds nine months.
Disease Control Rate
An ad hoc analysis of clinical outcomes in the cohort of 11 patients shows a disease control rate (DCR), the sum of overall response rate and rate of stable disease, of 63.6 percent, with a median follow-up of 15.4 weeks. In December 2020, the Company reported initial data showing a DCR of 87.5 percent in eight patients, with a median follow-up of 9.4 weeks. In this very difficult treatment-resistant patient population, at the time of the follow-up analysis, median progression-free survival (PFS) was 11.8 weeks. The landmark PFS rate by log-rank analysis at six months (26 weeks) was 33 percent.
Analysis of the updated data, using a validated immunohistochemistry assay during the eligibility screening period, shows that the rate of WT1 ovarian tumor positivity in this patient population remained high at approximately 63.6 percent. As of the time of this analysis, all patients are alive, and five patients (45.5 percent) are continuing to receive investigational therapy. Enrollment for this study is ongoing, with a target of approximately 20 total evaluable patients.
The safety profile of the GPS-pembrolizumab combination was similar to that seen with pembrolizumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site, consistent with previously performed clinical studies with GPS.
Immunobiological Data
CD8+ and CD4+ T-lymphocytes were isolated from peripheral blood mononuclear cells from three patients from whom samples had been collected both at baseline and at the time of the sixth GPS dose (i.e., 18 weeks after starting investigational therapy). The T-cells were assayed ex-vivo for immune responses against the pool of the four peptides that comprise GPS using the validated assay intracellular cytokine staining with fluorescence-activated single cell sorting (ICS-FACS) (Scorpion Biological Services, San Antonio, Texas), with appropriate positive and negative controls.
A total of five cytokine “channels” were used for the analysis (i.e., interferon-g, TNF-a, interleukin-2, CD107a and MIP-1b). The peptide re-challenge incubation period was seven days. At the 18-week time point versus pre-vaccination baseline, the assay demonstrated a relative increase in WT1-specific T-lymphocyte frequencies in peripheral blood averaging +242 percent (range: +104 to +385 percent across five cytokines) for CD8+ and +80.5 percent (range: +1 to +174 percent) for CD4+. There was also evidence of polyfunctional T-cell activation (increases in secretion of >2 cytokines) in two out of three patients (66 percent).
“Considering the overall poor prognosis in this particular clinical setting and based on the observed median PFS, overall survival and DCR in this study, combining GPS with the PD1 inhibitor pembrolizumab appears to be clinically promising as compared to bevacizumab-free salvage chemotherapy regimens and without the toxicity burden associated with the latter,” said Angelos Stergiou, M.D., Sc.D. h.c., President and CEO, SELLAS. “Patients treated with GPS plus pembrolizumab also appear to maintain a considerable degree of stable disease, as evidenced by the median DCR of 63.6 percent – all evaluable patients are alive. Continuing to review the clinical data will help us determine the fundamental value of the combination approach to fighting this disease. The initial trends are promising, and further maturity of the data and studying additional patients will allow us to draw more definitive conclusions regarding the clinical benefit. We expect to perform another set of similar ad hoc clinical and immunobiological analyses over the next six months as the study progresses.”
“Based on this early data, it is encouraging to see the induction of WT1-specific T-cell immune responses with the administration of GPS in combination with pembrolizumab with a validated complex ex-vivo immune response assay on peripheral blood from patients with platinum-refractory metastatic ovarian cancer who had undergone numerous prior therapies,” added Jeffrey S. Weber, M.D., Ph.D.; Deputy Director of the Perlmutter Cancer Center at New York University (NYU)-Langone Health; Co-Director of its Melanoma Research Program Center; and Chair of SELLAS’ Scientific Advisory Board. “Expansion of these results with data from additional patients, as well as at time points longer than 18 weeks (when such patient samples become available for testing), will be key in getting a more comprehensive picture of the combination immunotherapy’s biological effect.”
About Ovarian Cancer
Ovarian cancer is one of the most common gynecologic malignancies and the fifth most frequent cause of cancer death in women in the United States. Over 22,000 cases are diagnosed annually, and there are an estimated 15,500 deaths per year. The majority of patients have widespread disease at presentation. The five-year survival for the advanced-stage disease remains less than 30 percent. Combining GPS with the checkpoint inhibitor pembrolizumab, which beneficially and profoundly alters the tumor microenvironment (TME), is hypothesized to increase the proportion of patients who develop an immune response against their cancer and potentially improve their clinical outcome over pembrolizumab monotherapy, without the burden of additional toxicities in macroscopically measurable malignancies.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Keytruda® is a registered trademark of Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.
07.05.22 13:00
#2
Chalifmann3
hi
A mounting, mountain of evidence: Gps+Opdivo Mesothelioma trial patients have a 35.4 week median survival - as of last June, Ceo 'expecting median survival to be considerably longer' already 35.4 weeks 22 'for larger, mature data set".. Preliminary evidence from the Phase I trial of GPS administered as a combination therapy with nivolumab (Opdivo®) as a treatment for mesothelioma showed improvement in median survival of about half a year. Sellas reported median survival of 35.4 weeks after one month of GPS treatment, compared to 22 weeks for patients receiving standard of care (pemetrexed, a chemotherapy), for relapsed/refractory patients. This trial involved only four patients, however.
Such gains are “signals that a combination approach could have a benefit for patients,” Angelos Stergiou, M.D., Sc.D. h.c., president and CEO of Sellas, told BioSpace.
“The fundamental news from the mesothelioma study is that it seems to be safe and tolerable,” Stergiou said. “We went after a very serious disease state and showed a meaningful survival rate, even in the one patient with the sarcoma-toid variant.” That patient was diagnosed with Stage IV cancer and, so far, has survived 25 months – several months longer than usual for those receiving standard of care. (The expected survival for this patient under standard of care treatment was 12 to 18 weeks.)
“We expect to have follow-up data by the end of the year in a large patient sample,” he added.
“Sellas specializes in immunotherapy focused around the development of Wilms Tumor 1 antigen, which was designated as the number one immunotherapy target by the National Cancer Institute,” he said. WT1 antigen is expressed in the cell nuclei of 75% of mesotheliomas and 93% of ovarian serous carcinomas, for example. There are approximately 20 tumor types that overexpress WT-1 antigen, thus suggesting GPS could have substantial application.
GPS is made of four peptide chains. Two of those (CD4+ and CD8+) induce a strong innate response against the WT1 antigen and access multiple HLA types. When administered, therefore, the immune system recognizes and destroys cancer cells and can continue to do so, targeting recurring tumors and residual cancer cells. Consequently, Stergiou said, “Patients can stay in remission longer and, hopefully, this will translate into longer overall survival.”
In most cases, GPS is not envisioned as a stand-alone therapy. “GPS, when used alone, isn’t built to debulk tumors,” he said. Instead, it works synergistically with immunotherapies – notably, Opdivo® and Keytruda® – that modulate the hostile tumor microenvironment. Then, when GPS is injected, “GPS increases the antigen-specific effector T cells and shepherds them, focusing the immune response to specific epitopes for optimal T cell response,” Stergiou said.
Based on that mechanism of action, GPS may have potential as a monotherapy for patients who are in complete remission. That hypothesis is being tested in the ongoing Phase III study of AML patients.
“Our lead program (currently in Phase III) is in acute myeloid leukemia for patients in their second remission,” Stergiou said. Earlier, Phase II data, showed notably longer survival rates for patients in their second complete remission – 21 months for those receiving GPS therapy versus 5.4 months for those receiving standard of care treatment.
Such gains are “signals that a combination approach could have a benefit for patients,” Angelos Stergiou, M.D., Sc.D. h.c., president and CEO of Sellas, told BioSpace.
“The fundamental news from the mesothelioma study is that it seems to be safe and tolerable,” Stergiou said. “We went after a very serious disease state and showed a meaningful survival rate, even in the one patient with the sarcoma-toid variant.” That patient was diagnosed with Stage IV cancer and, so far, has survived 25 months – several months longer than usual for those receiving standard of care. (The expected survival for this patient under standard of care treatment was 12 to 18 weeks.)
“We expect to have follow-up data by the end of the year in a large patient sample,” he added.
“Sellas specializes in immunotherapy focused around the development of Wilms Tumor 1 antigen, which was designated as the number one immunotherapy target by the National Cancer Institute,” he said. WT1 antigen is expressed in the cell nuclei of 75% of mesotheliomas and 93% of ovarian serous carcinomas, for example. There are approximately 20 tumor types that overexpress WT-1 antigen, thus suggesting GPS could have substantial application.
GPS is made of four peptide chains. Two of those (CD4+ and CD8+) induce a strong innate response against the WT1 antigen and access multiple HLA types. When administered, therefore, the immune system recognizes and destroys cancer cells and can continue to do so, targeting recurring tumors and residual cancer cells. Consequently, Stergiou said, “Patients can stay in remission longer and, hopefully, this will translate into longer overall survival.”
In most cases, GPS is not envisioned as a stand-alone therapy. “GPS, when used alone, isn’t built to debulk tumors,” he said. Instead, it works synergistically with immunotherapies – notably, Opdivo® and Keytruda® – that modulate the hostile tumor microenvironment. Then, when GPS is injected, “GPS increases the antigen-specific effector T cells and shepherds them, focusing the immune response to specific epitopes for optimal T cell response,” Stergiou said.
Based on that mechanism of action, GPS may have potential as a monotherapy for patients who are in complete remission. That hypothesis is being tested in the ongoing Phase III study of AML patients.
“Our lead program (currently in Phase III) is in acute myeloid leukemia for patients in their second remission,” Stergiou said. Earlier, Phase II data, showed notably longer survival rates for patients in their second complete remission – 21 months for those receiving GPS therapy versus 5.4 months for those receiving standard of care treatment.
07.05.22 13:01
#3
Chalifmann3
hi
SELLAS Life Sciences Group, Inc. (SLS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Quote Lookup
2.5700-0.1000 (-3.75%)
At close: May 6 04:00PM EDT
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Quote Lookup
2.5700-0.1000 (-3.75%)
At close: May 6 04:00PM EDT
26.07.22 09:19
#4
Chalifmann3
hi
Everything you need to know about SLS: Company's cash runway will take the biotech into the fourth quarter of 2023, well beyond the Gps Phase 3 REGAL anticipated readout date and FDA Green Light in Q1/2. REGAL Readout will trigger an additional $50M from the $200M 3D Med License along with a massive increase in market cap Value. Eliminating any need for cheap dilution <- IMO this is Big
Gps' Lead investigator, the Chair of MD Andersons Leukemia department, sees the open label trial data, and has requested Expanded Access for additional AML patients, - basically confirming Gps is doing what it has done in all previous trials, including the Moffitt center phase 2, where Gps patients survived an average of 21 months compared to only 5.4 with the best available treatments. Control Patients in the REGAL phase 3 are on one of the 4 treatments that were used in the P2. There have been no new therapies since then.
GPs FDA approval has been preAuthorized at this First look / interim with an average OS of only 10 months.
SLS Keeps tracking towards its True North 2,500% ROI Q1/2 -> Share price will be Appreciating Bigly AHEAD of a Multibillion Dollar FDA Green light for treating AML patients in remission. 2 year cash runway, plus $55M more incoming from the $191.5 left in 3D Med License milestones.
Shorts Over sold this along with the tanking $XBI and need to buy back BUT No one is letting any go before the Huge FDA Pay Day Q1/Q2, hence all the desperate short board BS.
Have you ever seen so much short FUD ='s BUY MORE
For the First time in co history, they will be releasing binary data without any Need for Cash - pure short terror
Detailed Cash Analysis (in light of the Paid for articles July 5/9 that Exclude $25M April Cash Raise : )
Bottom Line: Plenty of Cash to Get to the multibillion FDA Green light, Q1/2 which simultaneously triggers $50M in Milestone $
$14.2 Bal Sheet+ $3.4Prepaid March 10Q + $23.6 proceeds April Raise $41.2M / 4.4M shares- total 20.4 now
$41.2 +$1M 3D Med milestone Paid in Q2 $42.2 on hand - $6M qtrly burn rate -- 7 Qtrs Current Cash
Cash Impact Events
Debits Gfh009 License -$4.5M Q2 + an Additional $5.5 Q3, 2023
(well after AML FDA Approval knowledge)
Credits: Gps Phase 2 Merck Joint Combination trial concluded in Q1 = savings
$191.5 M in Milestone money remaining on the 3D Med Greater China License + Low double digit Royalties
+ $5 to $7.5M 3D Med milestones in Q3/4 2022 for 5 Phase 2 Trials initiating
+ $5M 3D Med Milestone for Joining Ph 3 REGAL in Greater China (per 10q) / EU 2nd Half 2022
+ $25M 3D Med Milestone for Positive Ph3 Result Q1/2 2023
+ $25M 3D Med Milestong for BLA (Gps has FDA Fast Track Rolling submission and Approval 1st Half 2023
GFH009 $200M Market Value for Rare Pediatric Priority Review Voucher 2023
Bottom Line SLS may never need raise cash again
Gps' Lead investigator, the Chair of MD Andersons Leukemia department, sees the open label trial data, and has requested Expanded Access for additional AML patients, - basically confirming Gps is doing what it has done in all previous trials, including the Moffitt center phase 2, where Gps patients survived an average of 21 months compared to only 5.4 with the best available treatments. Control Patients in the REGAL phase 3 are on one of the 4 treatments that were used in the P2. There have been no new therapies since then.
GPs FDA approval has been preAuthorized at this First look / interim with an average OS of only 10 months.
SLS Keeps tracking towards its True North 2,500% ROI Q1/2 -> Share price will be Appreciating Bigly AHEAD of a Multibillion Dollar FDA Green light for treating AML patients in remission. 2 year cash runway, plus $55M more incoming from the $191.5 left in 3D Med License milestones.
Shorts Over sold this along with the tanking $XBI and need to buy back BUT No one is letting any go before the Huge FDA Pay Day Q1/Q2, hence all the desperate short board BS.
Have you ever seen so much short FUD ='s BUY MORE
For the First time in co history, they will be releasing binary data without any Need for Cash - pure short terror
Detailed Cash Analysis (in light of the Paid for articles July 5/9 that Exclude $25M April Cash Raise : )
Bottom Line: Plenty of Cash to Get to the multibillion FDA Green light, Q1/2 which simultaneously triggers $50M in Milestone $
$14.2 Bal Sheet+ $3.4Prepaid March 10Q + $23.6 proceeds April Raise $41.2M / 4.4M shares- total 20.4 now
$41.2 +$1M 3D Med milestone Paid in Q2 $42.2 on hand - $6M qtrly burn rate -- 7 Qtrs Current Cash
Cash Impact Events
Debits Gfh009 License -$4.5M Q2 + an Additional $5.5 Q3, 2023
(well after AML FDA Approval knowledge)
Credits: Gps Phase 2 Merck Joint Combination trial concluded in Q1 = savings
$191.5 M in Milestone money remaining on the 3D Med Greater China License + Low double digit Royalties
+ $5 to $7.5M 3D Med milestones in Q3/4 2022 for 5 Phase 2 Trials initiating
+ $5M 3D Med Milestone for Joining Ph 3 REGAL in Greater China (per 10q) / EU 2nd Half 2022
+ $25M 3D Med Milestone for Positive Ph3 Result Q1/2 2023
+ $25M 3D Med Milestong for BLA (Gps has FDA Fast Track Rolling submission and Approval 1st Half 2023
GFH009 $200M Market Value for Rare Pediatric Priority Review Voucher 2023
Bottom Line SLS may never need raise cash again
26.07.22 09:22
#5
Chalifmann3
hi,blendende aussichten
wir haben hier warscheinlich den heiligen Krebs Gral in den haenden bei dieser kleinen 50 mio Dollar company und so geht es weiter :
Get ready for an amazing end of 2022 - List of "Known" Catalysts
1. Final Phase 2 Gps Keytruda Combo Results - July/Aug. Partnership + upfront money potential MRK Joint Analysis Immunological data supporting the specific action of GPS in extending disease free survival and overall survival presented in an 'upcoming medical conference' - analysis to correlate Survival with IR's
2. Final Memorial Sloan Kettering Gps Opdivo Meso Results in 2ND Half + BMY Partnership + upfront Money potential -OS more than doubled life expectancy 10.5 months of OS which continues to expand, vs 22 weeks w BAT > IMP Opdivo Yervoy combination approved after extending OS 4 months https://www.fiercepharma.com/pharma/...-mesothelioma-death-risk-by-26
Combining a WT1 Cancer Vaccine (Galinpepimut-S) with Checkpoint Inhibition (Nivolumab) in Patients with WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study
Purpose
The purpose of this study is to assess the safety and effects of a cancer vaccine given with nivolumab immunotherapy in patients with pleural mesothelioma that continues to grow despite prior treatment. The vaccine is called galinpepimut-S and targets a protein called WT1, which is found on the surface of mesothelioma cells. It is mixed with a substance called montanide, which boosts the immune response.
Nivolumab inhibits a protein that normally puts the brakes on the immune response, enhancing the power of the immune system to find and destroy cancer cells. It is used to treat several types of cancer; its use in this study is considered investigational. It is believed that giving nivolumab in combination with a cancer vaccine will further enhance the immune response. Galinpepimut-S is given as an injection and nivolumab is given intravenously (by vein).
3. REGAL Enrollment Complete by the end of the year - This will bring big money and will start the clock ticking on billions in additional Market capitalization for SLS - Be Fully loaded Prior
4. GFH009 Trial Safety Data complete in Q3 and Final Data by the end of the year
- CDK9 Efficacy has been established many times over in other trials. safety has been the issue and Gfh009 has no Dose limitation, and is showing efficacy in patients who failed 6! 6 prior treatments!
5. 5, 3D MED Trials Launching, by the end of the Year, will trigger Multiple Milestone payments $5 - 7.5M + the 2 big kahunas, a positive Ph 3 results triggers 2, $25M payments in 2 or 3 qtrs - Imp as shorts will not be getting and cheap shares to cover with.
6. IDMC Halt for Efficacy - at any time
More likely than not 32 months deep into a trial where the Lead investigator is Requesting expanded Access and sees actual data!
The CEO has repeatedly stated the IDMC can halt the trial at any time if they see a clear Efficacy signal. The previous Gps Moffitt Center Phase 2 OS of 21 months Vs 5.4w BAT. Only a matter of time.
7. Gps Phase 2/3 MRD+ Trial initiation/ news
8. Gps Symposium PR
9. FDA Green light Gps 1st half of 23 is worth about 2 b in market cap value. Cr2 is the initial indication, Overall AML market expected to be appx 1B in annual revenue. Over a Million patients with WT1 Cancer each year - GPS is a blockbuster waiting happen.
We can only win bigly here in time
Gps has extended survival durations in Every single trial to date - All of them and is now showing efficacy against the most serious of cancers in combination with Keytruda and Opdivo
Gps 21m of OS vs 5.4 Cr2 Moffitt Center Phase 2 - First Phase 3 in process
Gps 67m of OS vs 25 Memorial Sloan Kettering Phase 2
Gps Opdivo 47% S at 2 years vs 7% for Ovarian cancer
Gps Opdivo 49 weeks (and counting) of OS vs 20 - 24 weeks End stage Mesothelioma Patients
Gps Keytruda OS of 10.5 m and counting vs 10.5 w existing therapy for end stage, platinum Refractory Oc
MD Andersons Leukemia department chairman running the Ph 3, who sees all the open label trial results, requesting Expanded Access, virtually confirms 2 things; 1. Gps is doing what it has done in every trial, cure patients and extend survival well beyond existing treatment, and 2. Guarantees Immediate off-label prescription and ultimate FDA Approved Expanded label to Cr1 / PostASCT which is 5x the $200M
Cr2 initial niche revenue projected by Cantor Fitz.
Also, now SLS has a 2 year cash runway, the Share Price will only appreciate approaching these Massively Valuable Catalysts
Get ready for an amazing end of 2022 - List of "Known" Catalysts
1. Final Phase 2 Gps Keytruda Combo Results - July/Aug. Partnership + upfront money potential MRK Joint Analysis Immunological data supporting the specific action of GPS in extending disease free survival and overall survival presented in an 'upcoming medical conference' - analysis to correlate Survival with IR's
2. Final Memorial Sloan Kettering Gps Opdivo Meso Results in 2ND Half + BMY Partnership + upfront Money potential -OS more than doubled life expectancy 10.5 months of OS which continues to expand, vs 22 weeks w BAT > IMP Opdivo Yervoy combination approved after extending OS 4 months https://www.fiercepharma.com/pharma/...-mesothelioma-death-risk-by-26
Combining a WT1 Cancer Vaccine (Galinpepimut-S) with Checkpoint Inhibition (Nivolumab) in Patients with WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study
Purpose
The purpose of this study is to assess the safety and effects of a cancer vaccine given with nivolumab immunotherapy in patients with pleural mesothelioma that continues to grow despite prior treatment. The vaccine is called galinpepimut-S and targets a protein called WT1, which is found on the surface of mesothelioma cells. It is mixed with a substance called montanide, which boosts the immune response.
Nivolumab inhibits a protein that normally puts the brakes on the immune response, enhancing the power of the immune system to find and destroy cancer cells. It is used to treat several types of cancer; its use in this study is considered investigational. It is believed that giving nivolumab in combination with a cancer vaccine will further enhance the immune response. Galinpepimut-S is given as an injection and nivolumab is given intravenously (by vein).
3. REGAL Enrollment Complete by the end of the year - This will bring big money and will start the clock ticking on billions in additional Market capitalization for SLS - Be Fully loaded Prior
4. GFH009 Trial Safety Data complete in Q3 and Final Data by the end of the year
- CDK9 Efficacy has been established many times over in other trials. safety has been the issue and Gfh009 has no Dose limitation, and is showing efficacy in patients who failed 6! 6 prior treatments!
5. 5, 3D MED Trials Launching, by the end of the Year, will trigger Multiple Milestone payments $5 - 7.5M + the 2 big kahunas, a positive Ph 3 results triggers 2, $25M payments in 2 or 3 qtrs - Imp as shorts will not be getting and cheap shares to cover with.
6. IDMC Halt for Efficacy - at any time
More likely than not 32 months deep into a trial where the Lead investigator is Requesting expanded Access and sees actual data!
The CEO has repeatedly stated the IDMC can halt the trial at any time if they see a clear Efficacy signal. The previous Gps Moffitt Center Phase 2 OS of 21 months Vs 5.4w BAT. Only a matter of time.
7. Gps Phase 2/3 MRD+ Trial initiation/ news
8. Gps Symposium PR
9. FDA Green light Gps 1st half of 23 is worth about 2 b in market cap value. Cr2 is the initial indication, Overall AML market expected to be appx 1B in annual revenue. Over a Million patients with WT1 Cancer each year - GPS is a blockbuster waiting happen.
We can only win bigly here in time
Gps has extended survival durations in Every single trial to date - All of them and is now showing efficacy against the most serious of cancers in combination with Keytruda and Opdivo
Gps 21m of OS vs 5.4 Cr2 Moffitt Center Phase 2 - First Phase 3 in process
Gps 67m of OS vs 25 Memorial Sloan Kettering Phase 2
Gps Opdivo 47% S at 2 years vs 7% for Ovarian cancer
Gps Opdivo 49 weeks (and counting) of OS vs 20 - 24 weeks End stage Mesothelioma Patients
Gps Keytruda OS of 10.5 m and counting vs 10.5 w existing therapy for end stage, platinum Refractory Oc
MD Andersons Leukemia department chairman running the Ph 3, who sees all the open label trial results, requesting Expanded Access, virtually confirms 2 things; 1. Gps is doing what it has done in every trial, cure patients and extend survival well beyond existing treatment, and 2. Guarantees Immediate off-label prescription and ultimate FDA Approved Expanded label to Cr1 / PostASCT which is 5x the $200M
Cr2 initial niche revenue projected by Cantor Fitz.
Also, now SLS has a 2 year cash runway, the Share Price will only appreciate approaching these Massively Valuable Catalysts
19.10.22 10:56
#6
Realmojoo
News!
LLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022
https://www.sellaslifesciences.com/investors/news/...022/default.aspx
https://www.sellaslifesciences.com/investors/news/...022/default.aspx
14.11.22 16:40
#8
Tiger
News und Minus 43 % ?!
https://ih.advfn.com/stock-market/NASDAQ/...vides-business-update-and
15.11.22 08:36
#10
Chalifmann3
hi
moin,was macht denn die phase 3 regal studie,sind die auf clinical hold oder was iss da los ?
15.11.22 14:38
#11
Tiger
SELLAS Life Sciences-Aktie fällt, da die Studie
zur akuten myeloischen Leukämie länger als erwartet stattfinden wird
https://finance.yahoo.com/news/...iences-shares-tumble-182518387.html
https://finance.yahoo.com/news/...iences-shares-tumble-182518387.html